Varenicline aggravates atherosclerotic plaque formation in nicotine-pretreated ApoE knockout mice due to enhanced oxLDL uptake by macrophages through downregulation of ABCA1 and ABCG1 expression

• Published in: Journal of pharmacological sciences Vol. 142; no. 1; pp. 9 - 15
• Main Authors: Koga, Mitsuhisa, Kanaoka, Yuki, Okamoto, Mana, Nakao, Yuki, Inada, Koshun, Takayama, Saki, Kataoka, Yasufumi, Yamauchi, Atsushi
• Format: Journal Article
• Language: English
• Published: Japan Elsevier B.V 01.01.2020; Elsevier
• Subjects: ABC cholesterol transporters; Animals; Atherosclerosis; ATP Binding Cassette Transporter 1 - genetics; ATP Binding Cassette Transporter 1 - metabolism; ATP Binding Cassette Transporter, Subfamily G, Member 1 - genetics; ATP Binding Cassette Transporter, Subfamily G, Member 1 - metabolism; Down-Regulation; Gene Expression Regulation - drug effects; Lipoproteins, LDL - metabolism; Macrophages - metabolism; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Nicotine; Nicotine - agonists; Nicotine - pharmacology; Plaque, Atherosclerotic - etiology; RAW 264.7 Cells; Scavenger receptors; Smoking Cessation Agents - toxicity; Varenicline; Varenicline - toxicity; ABC cholesterol transporters; Scavenger receptors; Varenicline; Atherosclerosis; Nicotine
• ISSN: 1347-8613; 1347-8648
• DOI: 10.1016/j.jphs.2019.11.002

Varenicline is a widely used and effective drug for smoking cessation. We previously reported that varenicline aggravates atherosclerosis in apolipoprotein E knockout (ApoE KO) mice. However, it remains unknown whether varenicline affects cardiovascular events in patients with nicotine addiction. Here, we examined the effect of varenicline on atherosclerotic plaque formation in nicotine-pretreated ApoE KO mice and oxidized low-density lipoprotein (oxLDL) uptake in nicotine-treated peritoneal macrophages. Varenicline caused significant progression of plaque formation in the whole aorta and aortic root and further accelerated the increased formation of a macrophage-rich plaque area in the aortic root in nicotine-pretreated ApoE KO mice. Varenicline (10 μM) enhanced oxLDL uptake in peritoneal macrophages. Furthermore, this treatment significantly further lowered the decreased protein levels of ATP-binding cassette (ABC) transporter without affecting the expression of scavenger receptors LOX-1 and CD36 in RAW264.7 cells treated with 100 nM nicotine. Varenicline enhanced nicotine-induced oxLDL uptake in macrophages through decreased expression of cholesterol efflux transporters ABCA1 and ABCG1 and thereby progressed atherosclerotic plaque formation. Taken together, we tentatively conclude that nicotine exposure before and/or during varenicline treatment can aggravate varenicline-increased atherosclerotic plaque formation and progression. Therefore, this enhanced risk requires special consideration when prescribing varenicline to smoker patients.